8-K: Allurion Technologies Reports Q1 2024 Results, Revenue Up 14% Sequentially

Allurion Technologies announced its first quarter 2024 financial results, showing a 14% sequential increase in revenue and a significant reduction in cash burn.

Summary

• Allurion Technologies reported a first quarter revenue of $9.4 million, which is a 14% increase compared to the fourth quarter of 2023, but a decrease compared to $14.1 million in the same period of 2023.
• Procedural volume, measured by new app users, increased by 12% year-over-year and 22% sequentially from the previous quarter.
• The company's cash burn was reduced to $8.4 million, down from $22 million in the fourth quarter of 2023, aligning with their target of approximately $30 million for the year.
• Gross profit margin was 73%, down from 79% in the same quarter of the previous year, due to lower production volumes.
• Operating expenses decreased by $6.8 million, contributing to a reduced loss from operations of $11.4 million compared to $13.9 million in the first quarter of 2023.
• Allurion closed a $48 million convertible senior secured note financing with RTW Investments, LP in April.
• The company launched its Virtual Care Suite (VCS) digital platform in the United States.
• Allurion reiterated its 2024 financial guidance, projecting revenue between $60 to $65 million, procedural volume growth of 20%, and gross margins of 77-79%.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with positive sequential revenue growth and reduced cash burn, but also a year-over-year revenue decrease and lower gross profit margins. The company's forward-looking statements are positive, but there are risks related to market conditions and competition.

Positives

• The company achieved a 14% sequential increase in revenue, indicating positive sales momentum.
• Procedural volume saw a significant increase both year-over-year and sequentially, suggesting growing adoption of the Allurion Program.
• The substantial reduction in cash burn demonstrates improved operational efficiency and cost management.
• The launch of the Virtual Care Suite in the U.S. expands the company's market reach and service offerings.
• The $48 million financing provides financial flexibility and simplifies the capital structure.
• The company is seeing positive results from a randomized, double-blind study showing significant reductions in serious comorbidities.

Negatives

• First quarter revenue of $9.4 million was lower than the $14.1 million reported in the same period of 2023.
• Gross profit margin decreased to 73% from 79% year-over-year due to lower production volumes.
• General and administrative expenses increased by $1.1 million compared to the first quarter of 2023 due to costs related to being a public company.
• The company experienced a loss from operations of $11.4 million for the quarter.

Risks

• The company experienced macroeconomic headwinds in certain markets, leading to lower re-order rates and reduced sales to manage credit risk.
• The decrease in gross profit margin due to lower production volumes could impact profitability.
• The company faces risks related to obtaining regulatory approval for and commercializing the Allurion Program.
• The company is subject to risks related to the evolution of the markets in which it competes and the impact of GLP-1 drugs.
• The company is subject to general economic, political and business conditions.

Future Outlook

Allurion reiterates its 2024 financial guidance, projecting procedural volume growth of 20%, revenue between $60 to $65 million, and gross margins of 77-79%. The company expects to receive AUDACITY trial data at the end of this year.

Management Comments

• Dr. Shantanu Gaur, Founder and Chief Executive Officer, stated that the strong performance in the first quarter was driven by continued growth in procedural volume.
• Dr. Gaur believes the increase in procedural volume reflects the strong demand for the Allurion Program.
• Dr. Gaur noted that the company improved its execution and increased efficiency across its operations, leading to a reduction in quarterly cash burn and operating expenses.
• Dr. Gaur believes the differentiated approach of the Allurion Program positions the company well to compete in the obesity management space.

Industry Context

The announcement comes amid increasing attention to the obesity management space, with Allurion positioning its procedureless balloon and virtual care suite as a differentiated offering. The company is also navigating the impact of GLP-1 drugs on the market.

Comparison to Industry Standards

• Allurion's sequential revenue growth of 14% is a positive sign, but the year-over-year decrease indicates challenges in maintaining consistent growth compared to the previous year.
• The reduction in cash burn to $8.4 million is a significant improvement, suggesting better cost management compared to previous quarters.
• The gross profit margin of 73% is lower than the 79% reported in the same period last year, which could be a concern if not addressed.
• Compared to other medical device companies in the weight loss space, Allurion's focus on a procedureless balloon and virtual care suite is a unique approach.
• Companies like ResMed and Intuitive Surgical, which focus on medical devices and digital health solutions, may be considered comparables, but Allurion's specific focus on weight loss and its unique product offering make direct comparisons challenging.

Stakeholder Impact

• Shareholders may view the sequential revenue growth and reduced cash burn positively, but the year-over-year revenue decrease and lower gross profit margins may raise concerns.
• Employees may be impacted by the company's cost reduction initiatives.
• Customers may benefit from the launch of the Virtual Care Suite and the expansion of the Allurion Program.
• Suppliers may be affected by changes in production volumes and sales.

Next Steps

• The company will continue to focus on driving procedural volume growth and expanding its market reach.
• Allurion will work towards receiving AUDACITY trial data at the end of this year.
• The company will focus on building strong partnerships with U.S. providers.
• Allurion will continue to execute its cost reduction initiatives.

Key Dates

Keywords

Allurion, weight loss, gastric balloon, virtual care, obesity, financial results, revenue, cash burn, procedural volume, digital health